Abstract:Multiple myeloma (MM) is the 2nd most frequently diagnosed blood cancer after non-Hodgkin's lymphoma. The present study aimed to identify the differentially expressed genes (DEGs) between the control and pristimerin-treated MM cell lines. We examined the GSE14011 microarray dataset and screened DEGs with GEO2R statistical tool using the inbuilt limma package. We used a bioinformatics pipeline to identify the differential networks, signaling cascades, and the survival of the hub genes. We implemented two different enrichment analysis including ClueGO and Metacore™, to get accurate annotation for most significant DEGs. We screened the most significant 408 DEGs from the dataset based on p-values and logFC values. Using protein network analysis, we found the genes UBC, HSP90AB1, HSPH1, HSPA1B, HSPA1L, HSPA6, HSPD1, DNAJB1, HSPE1, DNAJC10, BAG3, and DNAJC7 had higher node degree distribution. In contrast, the functional annotation provided that the DEGs were predominantly enriched in B-cell receptor signaling, unfolded protein response, positive regulation of phagocytosis, HSP70, and HSP40-dependent folding, and ubiquitin-proteasomal proteolysis. Using network algorithms, and comparing enrichment analysis, we found the hub genes enriched were INHBE, UBC, HSPA1A, HSP90AB1, IKBKB, and BAG3. These DEGs were further validated with overall survival and gene expression analysis between the tumor and control groups. Finally, pristimerin effects were validated independently in a cell line model consisting of IM9 and U266 MM cells. Pristimerin induced in vitro cytotoxicity in MM cells in a dose-dependent manner. Pristimerin inhibited NF-κB, induced accumulation of ubiquitinated proteins and inhibited HSP60 in the validation of bioinformatics findings, while pristimerin-induced caspase-3 and PARP cleavage confirmed cell death. Taken together, we found that the identified DEGs were strongly associated with the apoptosis induced in MM cell lines due to pristimerin treatment, and combinatorial therapy derived from pristimerin could act as novel anti-myeloma multifunctional agents.

Pristimerin‐induced Uveal Melanoma Cell Death Via Inhibiting PI3K/Akt/FoxO3a Signalling Pathway

Pristimerin Effectively Inhibits the Malignant Phenotypes of Uveal Melanoma Cells by Targeting NF-κB Pathway

Pristimerin Inhibits Glioma Progression by Targeting AGO2 and PTPN1 Expression via miR-542-5p.

The application of natural compounds in uveal melanoma drug discovery

Pristimerin Demonstrates Anticancer Potential in Colorectal Cancer Cells by Inducing G1 Phase Arrest and Apoptosis and Suppressing Various Pro-Survival Signaling Proteins

Pristimerin Triggers AIF-dependent Programmed Necrosis in Glioma Cells Via Activation of JNK.

Pristimerin induces apoptosis and inhibits proliferation, migration in H1299 Lung Cancer Cells

Pristimerin induces apoptosis and autophagy via activation of ROS/ASK1/JNK pathway in human breast cancer in vitro and in vivo

Pristimerin exerts antitumor activity against MDA-MB-231 triple-negative breast cancer cells by reversing of epithelial-mesenchymal transition via downregulation of integrin β3

Verteporfin Induces Apoptosis and Eliminates Cancer Stem-Like Cells in Uveal Melanoma in the Absence of Light Activation.

Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation

Pristimerin Induces Apoptosis In Imatinib-Resistant Chronic Myelogenous Leukemia Cells Harboring T315i Mutation By Blocking Nf-Kappa B Signaling And Depleting Bcr-Abl

Pristimerin Exacerbates Cellular Injury in Conditionally Reprogrammed Patient-Derived Lung Adenocarcinoma Cells by Aggravating Mitochondrial Impairment and Endoplasmic Reticulum Stress through EphB4/CDC42/N-WASP Signaling

Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells

Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells

Analysis of signaling cascades from myeloma cells treated with pristimerin

Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGFβR1, GNAQ, WASL, and RAC1

miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGF beta R1, GNAQ, WASL, and RAC1

Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma

Highly Tumoricidal Efficiency of Non-Oxidized MXene-Ti3C2Tx Quantum Dots on Human Uveal Melanoma.